Enhancing Cancer Immunotherapy Via Activation of Innate Immunity

Seminars in Oncology
Jacob L Goldberg, Paul M Sondel

Abstract

Given recent technological advances and advances in our understanding of cancer, immunotherapy of cancer is being used with clear clinical benefit. The immunosuppression accompanying cancer itself, as well as with current cancer treatment with radiation or chemotherapy, impairs adaptive immune effectors to a greater extent than innate effector cells. In addition to being less suppressed, innate immune cells are capable of being enhanced via immune-stimulatory regimens. Most strategies being investigated to promote innate immune responses against cancer do not require complex, patient-specific, ex vivo cellular or molecular creation of therapeutic agents; thus they can, generally, be used as "off the shelf" therapeutics that could be administered by most cancer clinics. Successful applications of innate immunotherapy in the clinic have effectively targeted components of the innate immune response. Preclinical data demonstrate how initiation of innate immune responses can lead to subsequent adaptive long-term cancer immunity. We hypothesize that integration of innate immune activation strategies into combination therapies for cancer treatment will lead to more effective and long-term clinical benefit.

References

Jan 1, 1992·Cancer Immunology, Immunotherapy : CII·R HandgretingerD Niethammer
Jun 19, 1986·The New England Journal of Medicine·M P LinkJ A Kirkpatrick
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R HandgretingerD Neithammer
Jan 16, 1998·Immunity·M UhrbergP Parham
Mar 1, 2000·Proceedings of the National Academy of Sciences of the United States of America·S KimW M Yokoyama
Apr 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·M J WilsonJ Trowsdale
Oct 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Irene Y CheungNai-Kong V Cheung
Mar 23, 2004·Annual Review of Immunology·Gavin P DunnRobert D Schreiber
Jul 15, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alberto MantovaniAntonio Sica
Jul 23, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zane C NealPaul M Sondel
Mar 28, 2006·Journal of Leukocyte Biology·Hillary D LumAlexander L Rakhmilevich
Oct 30, 2007·Blood Cells, Molecules & Diseases·Loredana RuggeriAndrea Velardi
Jan 25, 2008·Cancer Immunology, Immunotherapy : CII·Alexander L RakhmilevichPaul M Sondel
Jun 25, 2009·Expert Opinion on Investigational Drugs·Brett H YamanePaul M Sondel
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hanne Krogh JensenHans von der Maase
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey M VenstromKatharine C Hsu
Jan 19, 2010·Nature Medicine·A McGarry HoughtonSteven D Shapiro
Mar 2, 2010·MAbs·Rolf LinkeDiane Seimetz
Apr 27, 2010·Expert Opinion on Biological Therapy·Theresa L Whiteside
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Sep 3, 2010·Nature Reviews. Drug Discovery·Aaron L NelsonJanice M Reichert
Oct 1, 2010·The New England Journal of Medicine·Alice L YuUNKNOWN Children's Oncology Group
Mar 24, 2011·Cancer Research·Alyssa D Gregory, A McGarry Houghton
Jul 28, 2011·Cancer Immunology, Immunotherapy : CII·Jennifer A A GubbelsJoseph Connor
Jan 13, 2012·Current Opinion in Immunology·Suzanne L TopalianDrew M Pardoll
Feb 4, 2012·Nature Reviews. Drug Discovery·Lorenzo GalluzziGuido Kroemer
Aug 7, 2012·The Journal of Clinical Investigation·Nidale TarekKatharine C Hsu
Aug 8, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nai-Kong V CheungShakeel Modak
Aug 31, 2012·Oncoimmunology·Lorenzo GalluzziGuido Kroemer

❮ Previous
Next ❯

Citations

May 1, 2019·Journal for Immunotherapy of Cancer·Weiqing JingMichael B Dwinell
Feb 6, 2020·Expert Opinion on Therapeutic Patents·Cristina M QuintellaGuilherme M Quintella
Apr 26, 2018·Frontiers in Immunology·Heleen H Van AckerViggo F Van Tendeloo
Sep 29, 2017·Frontiers in Immunology·Melvin Kantono, Beichu Guo
Feb 22, 2017·International Journal of Molecular Sciences·Kai LiMing Shi
Dec 17, 2020·Frontiers in Immunology·Peter C HartLawrence A Potempa
Mar 24, 2021·Cell Communication and Signaling : CCS·Zhen ZhangXuefei Tian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.